Filing Overview
This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for May 2024 and signed on May 14, 2024. The filing concerns amendments to two unsecured short-term loans from Ronald Hafner, the company’s Chairman of the Board.
Debt and Liquidity
- On September 28, 2023, the company borrowed CHF 500,000; on November 15, 2023, it borrowed CHF 250,000.
- The aggregate principal amount is CHF 750,000. Both loans bear interest at 10% per annum.
- The loans were originally scheduled to mature on November 30, 2023.
- The September 2023 loan was previously extended to December 31, 2024 under a March 18, 2024 addendum.
- On May 13, 2024, the company entered into additional addenda extending the maturity dates of both loans to June 30, 2025.
- The filing does not provide updated accrued interest, cash balances, liquidity measures, repayment terms beyond the maturity extensions, or other debt balances.
Material Changes and Unusual Items
The principal reported change is the further extension of both insider-provided short-term loans from their prior maturity arrangements to June 30, 2025. The loans are unsecured and provided by the company’s Chairman, making the transaction a related-party financing arrangement.
Outlook, Risks, and Contingencies
- The maturity extensions defer repayment obligations but do not reduce the CHF 750,000 principal or the 10% annual interest obligation.
- Continued reliance on financing from an executive-related lender may indicate liquidity or funding needs; the filing does not state management’s broader financing outlook.
- The filing provides no operating guidance, revenue outlook, profitability forecast, or discussion of repayment sources.
- The complete terms are contained in Exhibits 99.1 and 99.2, which should be reviewed for any additional covenants, fees, default provisions, or other amendments.
Key Facts for Investors to Verify
- Confirm the final principal and accrued interest owed under each loan as of the latest reporting date.
- Review Exhibits 99.1 and 99.2 for complete amendment terms and any changes beyond the maturity dates.
- Assess the company’s available cash, near-term funding requirements, and ability to repay or refinance the loans by June 30, 2025.
- Verify related-party disclosure and the accounting treatment of the loans and interest expense.
- Note that the supplied filing identifies the issuer as NLS Pharmaceutics Ltd.; it does not reference Newcelx Ltd.